Method and device for determining a finished medicinal product

Abstract

The invention relates to a method for determining a finished medicinal product, having the following steps: providing a finished medicinal product to be determined in closed primary packaging; measuring an NIR measurement spectrum for the finished medicinal product to be determined through the closed primary packaging; comparing the NIR measurement spectrum with an NIR reference spectrum, which is associated with a medicinal product or an active ingredient of a medicinal product; and determining that the finished medicinal product to be determined contains the medicinal product or the medicinal product active ingredient when the NIR measurement spectrum and the NIR reference spectrum correspond within a margin for error. The invention further relates to a device for determining a finished medicinal product.

Claims

1. A method for determining a finished medicinal product having the following steps: providing a finished medicinal product to be determined in closed primary packaging; measuring an NIR (near infrared) measurement spectrum for the finished medicinal product to be determined through the closed primary packaging; comparing the NIR measurement spectrum with an NIR (near infrared) reference spectrum, which is associated with a medicinal product or an active ingredient of a medicinal product, wherein the NIR measurement spectrum is compared with the NIR reference spectrum which is assigned to a medicinal product active ingredient formed as a biosimilar; and determining that the finished medicinal product to be determined contains the medicinal product or the medicinal product active ingredient when the NIR measurement spectrum and the NIR reference spectrum correspond within a margin for error.

2. The method according to claim 1, characterized in that the comparison of the NIR measurement spectrum with the NIR reference spectrum furthermore has the following steps: determining a first spectral subrange of an overall spectral range captured during the measurement of the NIR measurement spectrum; comparing the NIR measurement spectrum and the NIR reference spectrum for the first spectral subrange; and determining that the finished medicinal product to be determined contains the medicinal product or the medicinal product active ingredient when the NIR measurement spectrum and the NIR reference spectrum in the first spectral subrange correspond within a first margin for error.

3. The method according to claim 2, characterized in that the comparison of the NIR measurement spectrum with the NIR reference spectrum furthermore has the following steps: determining a second spectral subrange of an overall spectral range captured during the measurement of the NIR measurement spectrum, wherein the second spectral subrange within the overall spectral range is separated from the first spectral range; comparing the NIR measurement spectrum and the NIR reference spectrum for the second spectral subrange; and determining that the finished medicinal product to be determined contains the medicinal product or the medicinal product active ingredient if the NIR measurement spectrum and the NIR reference spectrum in the second spectral subrange correspond within a second margin for error.

4. The method according to claim 3, characterized in that the second margin for error is different from the first margin for error.

5. The method according to claim 3, characterized in that the finished medicinal product to be determined is determined as containing the medicinal product active ingredient nab-paclitaxel when the NIR measurement spectrum and the NIR reference spectrum correspond in a first spectral subrange from 5600 cm.sup.−1 to 7000 cm.sup.−1 and in a second spectral subrange from 4000 cm.sup.−1 to 5000 cm.sup.−1 within a first margin for error.

6. The method according to claim 2, characterized in that the finished medicinal product to be determined is determined as containing the medicinal product active ingredient trastuzumab emtansine when the NIR measurement spectrum and the NIR reference spectrum correspond in a first spectral subrange from 3500 cm.sup.−1 to 5500 cm.sup.−1, alternatively from 4000 cm.sup.−1 to 5000 cm.sup.−1 and further alternatively from 4150 cm.sup.−1 to 5150 cm.sup.−1 within the first margin for error.

7. The method according to claim 2, characterized in that the medicinal product active ingredient is determined as containing infliximab (originator) if when the NIR measurement spectrum and the NIR reference spectrum correspond in a first spectral subrange from 3500 cm.sup.−1 to 5500 cm.sup.−1, alternatively from 4000 cm.sup.−1 to 5000 cm.sup.−1 and further alternatively from 4500 cm.sup.−1 to 4750 cm.sup.−1 within a first margin for error.

8. The method according to claim 1, characterized in that the NIR measurement spectrum is compared with a plurality of NIR reference spectrums from a spectral reference library.

9. The method according to claim 1, characterized in that the finished medicinal product to be determined is in a closed disposable primary packaging.

10. The method according to claim 1, characterized in that the finished medicinal product to be determined is in a container of the closed disposable primary packaging, which container is made of glass and/or plastics material.

11. The method according to claim 1, characterized in that, when the NIR measurement spectrum is measured, at least one optical measuring method from the following group of optical measuring methods is used: absorption measurement, reflection measurement and transmission measurement.

12. A device for determining a finished medicinal product, comprising: a test sample receptacle adapted to receive, as a test sample, a finished medicinal product to be determined in a closed primary packaging; a measuring device adapted to capture an NIR measurement spectrum for the finished medicinal product to be determined through the closed primary packaging; and an evaluation unit adapted to compare the NIR (near infrared) measurement spectrum with an NIR (near infrared) reference spectrum which is assigned to a medicinal product or a medicinal product active ingredient, wherein the NIR reference spectrum is assigned to a medicinal product active ingredient formed as a biosimilar; and to determine that the finished medicinal product to be determined contains the medicinal product or the medicinal product active ingredient when the NIR measurement spectrum and the NIR reference spectrum correspond within a margin for error.

Description

DESCRIPTION OF EMBODIMENTS

(1) Further embodiments are explained in more detail below with reference to the drawings. In the drawings:

(2) FIG. 1 is a schematic representation of a device for determining a finished medicinal product using NIR spectroscopy;

(3) FIG. 2 is a schematic representation of a method for determining a finished medicinal product;

(4) FIG. 3 is a graphic representation of an NIR measurement spectrum for Abraxane (nab-paclitaxel), wherein the absorption and dependence on the wave number is shown;

(5) FIG. 4 is a graphic representation of the first derivative for the NIR measurement spectrum from FIG. 3;

(6) FIG. 5 is a graphic representation of the vector-normalized NIR measurement spectrum from FIG. 3;

(7) FIG. 6 is a graphic representation of preprocessed NIR spectrums for four finished medicinal products; and

(8) FIG. 7 is a graphic representation of a spectral section for the NIR spectrums from FIG. 6.

(9) FIG. 1 is a schematic representation of a device for determining a finished medicinal product by means of NIR spectroscopy. The NIR spectral range captures wavelengths in the range from 780 nm to 2,500 nm (12,800 to 4,000 cm.sup.−1 wave number).

(10) A sample 3 of a finished medicinal product to be determined in primary packaging 4 is arranged on a sample receptacle 1 of a measuring device 2. A closure 5 of the primary packaging 4 is a single-use closure. The primary packaging 4 is formed with a container 6, which is made, for example, of plastics material or glass, such as brown glass.

(11) The sample 3 of the finished medicinal product to be determined is inspected in the closed primary packaging 4 by irradiating NIR light beams 7 across the region of the bottom 8 of the container 6, which beams penetrate the container wall and thus arrive at the sample 3. Prior to this process, the NIR light beams 7 are preferably deflected by a mirror 9 and guided through an Ulbricht sphere 10. For a measurement, a further mirror 11 is displaced from the position shown in FIG. 1 so that the beam path on the bottom 8 of the container 6 is released.

(12) Due to the irradiation of the NIR light beams 7 on the sample 3, NIR measurement light beams (not shown) are created, which travel from the container 6 to the Ulbricht sphere 10 and are deflected there toward a detector 12, along a path 14.

(13) With the further mirror 11, the beam path can be interrupted and opened. The interruption shown in FIG. 1 may, for example, be used for a reference measurement, i.e., for a measurement without a sample effect, for example so as to improve the signal-to-noise ratio. When the further mirror 11, which is configured as a gold mirror, for example, is arranged in the beam path, the irradiated NIR light beams 7 according to FIG. 1 are refracted without reaching the sample 3 and arrive at the detector 12. If the further mirror 11 is arranged laterally to the beam path (not shown), the measurement can be carried out on the sample 3 which is to be determined.

(14) Furthermore, an evaluation unit 13 is provided in which the NIR measurement spectrums captured by means of the detector 12 can be processed and compared with the NIR reference spectrums. The evaluation unit may comprise one or more processors and a memory in which a software application is stored with which the processing of the spectral signals measured can be executed.

(15) FIG. 2 is a schematic representation of the course of a method for determining a finished medicinal product. In step 20, the finished medicinal product to be determined is provided in the closed primary packaging 3. In step 21, one or a plurality of NIR measurement spectrums are measured, wherein the NIR light beams 6 are irradiated through the closed primary packaging 3. The NIR measurement spectrum is compared with an NIR reference spectrum (step 22), which is associated with a medicinal product or a medicinal product active ingredient. By means of the evaluation unit 12, it is determined whether the finished medicinal product to be determined contains the medicinal product or the medicinal product active ingredient (step 23) if the NIR measurement spectrum and the NIR reference spectrum correspond within a margin for error.

(16) Chemometric methods are used for evaluating and comparing NIR measurement spectrums and NIR reference spectrums. For example, these may include a data preprocessing, whereupon the chemometric evaluation takes place. In the context of data preprocessing of the spectrums, a vector normalization may be performed, for example. One or more derivatives for the spectrums may be calculated as well. The generally known Savitzky-Golay algorithm may be used to derive the spectrums.

(17) In the context of the chemometric evaluation, the spectrums (which may have been pretreated) are then compared. In particular, a spectral distance between the spectrums to be compared is determined. Various methods for the calculation of the spectral distance are known. The Euclidian distance may be determined, for example. Alternatively or additionally, it may be provided that the Mahalanobis distance is determined to identify the similarity of the spectrums to be compared within the specified margin for error.

(18) Further embodiments are explained below. The NIR measurements were determined at room temperature.

(19) The finished medicinal product Remicade contains the medicinal product active ingredient infliximab. This medicinal product constitutes the original product. At least one biosimilar, sold by various companies, is known. By means of a wavelength range selection from approximately 4592 cm.sup.−1 to approximately 4736 cm.sup.−1, the originator can be distinguished from the biosimilar (cf. pretreated, complete spectrums of four finished medicinal products in FIG. 6). The embodiments concern Remicade and the related biosimilars: Remisa, Inflectra and Flixabi.

(20) The spectral differences shown in FIG. 7 lead to the fact that the two active ingredients (originator and biosimilar), which, based on tests, differ in their glycosylation pattern (cf., for example, “arznei-telegramm”, 6/15, 46th volume, 12 Jun. 2015), can be distinguished. This is generally possible only with a complex LC-MS method.

(21) The method for determining a finished medicinal product was used in one embodiment for determining Remicade in a finished medicinal product. For this purpose, a plurality of consecutive comparison steps were performed for the comparison of NIR measurement spectrums and NIR reference spectrums in which selected spectral ranges were compared to achieve the determination or identification of one or more active ingredients in the respective step or to exclude them.

(22) Table 1 below shows a summary overview of the comparison steps that were performed.

(23) TABLE-US-00001 TABLE 1 Wave number Steps Description range(s) [cm.sup.−1] 1 Dividing into groups 10040-4080 2 Determining Kyprolis and separating  7760-7200; a further group of chemically defined  6992-5336; medicinal product active ingredients  5136-4104 3 Determining Abraxane  6904-5600;  5000-4000 4 Determining Etopophos  6968-6584 5 Determining Orencia, Ivemend and  6856-5400, separating from Adcetris and Myocet  4992-4776,  4400-4136 6 Determining Entyvio  6192-6128;  5592-5544;  5096-4952 7 Determining Yondelis, separating  7016-5384; into two groups  5008-4072 8 Dividing into two groups  6000-5600;  4904-4144 9 Determining Remicade and/or bio-  4736-4592 similars

(24) In the spectral comparison steps, the NIR measurement spectrum is always compared with one or more NIR reference spectrums. In step 1, a rough separation into groups A and B is performed on the basis of the wave number range from approximately 10,040 cm.sup.−1 to approximately 4,080 cm.sup.−1. All the NIR spectrums are normalized in this step and the data is preprocessed to minimize physical factors that influence the spectrum. To prepare for the comparison, it is provided here that the spectrums are prepared. Vector normalization is one of the methods used to prepare the spectrums. In this method, average values are first determined for the measured optical parameter in order then to deduct the average values from the measurement spectrum, wherein this data preparation may be performed for all or some of the spectral values (wavelength, wave number). Alternatively or additionally, it may be provided that derivatives are determined for the measured values. Afterwards, the spectrums are compared. For this purpose, for example, the Euclidean distance and/or the Mahalanobis distance may be used.

(25) In the next step 2, the separation of Kyprolis and a group of chemically defined cytostatic drugs is performed. In this process, the interfering water bands are excluded. In addition, a pretreatment similar to the one in step 1 is performed with the individually optimized settings. The separation is performed by means of the Mahalanobis distance.

(26) In step 3, Abraxane is identified or determined, i.e., it is ruled out that it is Abraxane.

(27) Analogously, Etopophos is identified in step 4, Adcentris, Myocet, Ivemend and Orencia in step 5 and Entyvio in step 6.

(28) In step 7, Yondelis is identified or determined and a further division into two groups is performed. In step 8, a further distinction is made between two groups of monoclonal antibodies. One group now still only contains the different Infliximab FAM. These are differentiated in step 9 with the specific wave number range.

(29) Table 2 below shows further embodiments for the determination of active ingredients in finished medicinal products by means of the technology described.

(30) TABLE-US-00002 TABLE 2 Cons. Active ingredient in the Wave number No. medicinal product range(s) [cm.sup.−1 Product example 1 Nab-paclitaxel 7100-550, Abraxane 100 mg 5000-4000 Celgene 2 Brentuximab vedotin 5000-4000 Adcetris 50 mg Takeda 3 Pemetrexed 6300-5900, Alimta 500 mg Lilly 5200-4900 4 Belimumab 5900-5300 Benlysta 120 mg gsk 5 Belimumab 5900-5300 Benlysta 400 mg gsk 6 Vedolizumab 6300-6000, Entyvio 300 mg Tadeka 5600-4800 7 lnfliximab (biosimilar) 4800-4300 Flixabi 100 mg SamsungBioe-pis 8 Trastuzumab 5900-5300 Herceptin 150 mg Roche 9 lnfliximab (biosimilar) 4800-4300 Inflectra 100 mg Hospira 10 Trastuzumab emtansine 4900-4400 Kadcyla 100 mg Roche 11 Trastuzumab emtansine 4900-4400 Kadcyla 160 mg Roche 12 Pembrolizumab 4900-4400 Keytruda 50 mg MSD 13 Doxorubicin 5000-4000 Myocet 50 mg TEVA 14 Abatacept 7000-5300, Orencia 250 mg b-ms 5100-4000 15 lnfliximab (original) 4800-4300 Remicade 100 mg MSD 16 lnfliximab (biosimilar) 4800-4300 Remsima 100 mg Celltrion 17 Bortezomib 7100-6400, Velcade 3.5 mg Janssen 6200-5800, 5300-4900 18 Azacitidin 6300-5900, Vidaza 100 mg Celgene 5200-4900

(31) The features disclosed in the description above, the claims and the drawings may be of significance for the realization of the different embodiments both individually and in any combination.